<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>A closer look</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Tracking hantavirus across the globe</title>
      <description>
        <![CDATA[The recent hantavirus outbreak aboard the MV Hondius cruise ship has brought increased attention to an infection for which there are no widely available or FDA-approved therapeutics or vaccines, with limited research occurring only at the earliest stages. The rare Andes strain identified in the outbreak is known for human-to-human transmission, although the original infection comes from rodents. While hantavirus does not spread as easily as an infection like COVID-19, the mortality rate, at 30% to 40%, is significantly greater, and serves as another example as to why biopharmas must be at least two steps ahead with technology that can pivot to quickly address the spread of infectious diseases. Read <em>BioWorld</em>’s ongoing coverage of the current hantavirus outbreak.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731052</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731052-tracking-hantavirus-across-the-globe</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Hantavirus-cells.webp?t=1778264511" type="image/jpeg" medium="image" fileSize="478857">
        <media:title type="plain">Hantavirus cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Hantavirus is ‘sentinel’ more than acute pandemic threat</title>
      <description>
        <![CDATA[News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press conference on Thursday, officials from the WHO did their best to calm the public’s fears that the <em>MV Hondius</em>, the ship currently heading to the Canary Islands with its remaining passengers plus assorted medical, WHO and European Center for Disease Prevention and Control staff, is the 2026 version of the <em>Diamond Princess</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731113</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731113-hantavirus-is-sentinel-more-than-acute-pandemic-threat</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Cruise-ship.webp?t=1778189869" type="image/jpeg" medium="image" fileSize="257901">
        <media:title type="plain">Close up of bow of cruise ship</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel method BOOSTs organ growth after transplantation</title>
      <description>
        <![CDATA[A major challenge in tissue engineering is not only achieving the correct cellular organization of an engineered tissue, but also expanding it to a clinically useful size after implantation. Researchers from the Wyss Institute at Harvard University have developed a synthetic biology platform that genetically programs tissues to grow large organ implants on demand. Building on a 2017 study suggesting engineered liver tissues could respond to regenerative signals released after injury, the researchers set out to identify and harness those cues.
<br><br>
  “If we could figure out what those signals were, we could synthetically drive these factors locally in an implant to control its growth ourselves,” first author Amy Stoddard told <em>BioWorld</em>. Stoddard is a postdoctoral researcher at the Wyss Institute.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730717</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730717-novel-method-boosts-organ-growth-after-transplantation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Neon-arrows.webp?t=1777389173" type="image/jpeg" medium="image" fileSize="548927">
        <media:title type="plain">Pink and blue neon arrows demonstrating acceleration</media:title>
      </media:content>
    </item>
    <item>
      <title>Psychedelic space expanding on Trump’s EO</title>
      <description>
        <![CDATA[Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a surge in investment in companies researching and developing psychedelic drugs to treat mental health issues. The EO, Accelerating medical treatments for serious mental illness, is intended to address the increasing burden of suicide and serious mental illness, which impacts more than 14 million Americans.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730465</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730465-psychedelic-space-expanding-on-trumps-eo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Green-arrow-on-blue-abstract-background.webp?t=1776721603" type="image/jpeg" medium="image" fileSize="992857">
        <media:title type="plain">Green arrow on blue abstract background</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings steady at $8.8B in Q1, despite volume drop</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. The 2026 total exceeds $6.45 billion in Q1 2024 and $4.69 billion in Q1 2023, indicating continued recovery from the weaker funding environment that followed the 2021 peak. While still below the $16.59 billion recorded in Q1 2019 and the pandemic-era highs, the data suggest that financing activity has stabilized at a higher baseline, with 2026 maintaining momentum despite a slight year-over-year pullback.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730396</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730396-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Layered-charts.webp?t=1706913970" type="image/jpeg" medium="image" fileSize="137002">
        <media:title type="plain">Layered  charts </media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730211</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730211-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Blockbuster deals push med-tech M&amp;A above $40B in Q1 2026</title>
      <description>
        <![CDATA[Med-tech deal value, excluding M&As, totaled $628.41 million in the first quarter (Q1) of 2026, an increase of about 322% from the $149.08 million recorded in Q1 2025 though a 36% drop from Q4 2025‘s $978.58 million. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730075</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730075-blockbuster-deals-push-med-tech-m-and-a-above-40b-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/MA-cityscape.webp?t=1597870997" type="image/png" medium="image" fileSize="580371">
        <media:title type="plain">M&amp;A cityscape</media:title>
      </media:content>
    </item>
    <item>
      <title>Emerging therapeutic strategies for Parkinson’s at ADPD 2026</title>
      <description>
        <![CDATA[Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the abnormal accumulation of α-synuclein, a protein that forms toxic aggregates and spreads between cells, damaging them. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), held from March 17 to 21, 2026, in Copenhagen, several strategies were presented that aim to modify the course of the disease and offer real alternatives to purely symptomatic treatments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729789</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729789-emerging-therapeutic-strategies-for-parkinsons-at-adpd-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinsons-disease-PD-neuron-hands.webp?t=1774276432" type="image/jpeg" medium="image" fileSize="923725">
        <media:title type="plain">Art concept for Parkinson's disease</media:title>
      </media:content>
    </item>
    <item>
      <title>Biopharma deal value jumps 60% to start 2026</title>
      <description>
        <![CDATA[Biopharma deal value reached $61.17 billion in the first two months of 2026, roughly a 60% increase from the $38.11 billion logged in the same period of 2025 and marking the strongest early year total in <em>BioWorld’s</em> records. The surge was driven by unusually strong activity in both months, with $31.16 billion in January and $30.01 billion in February.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729497</guid>
      <pubDate>Fri, 13 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729497-biopharma-deal-value-jumps-60-to-start-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Arrows-up.webp?t=1588977069" type="image/png" medium="image" fileSize="203844">
        <media:title type="plain">Arrows pointing upward</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech outlook 2026: exits, financings, headwinds</title>
      <description>
        <![CDATA[What does med tech in 2026 look like? Uncertainty remains. Global investors are confident about exit opportunities in the year ahead. But financing will be targeted. For the med-tech companies, geopolitical tensions continue to create headwinds, particularly for the European firms navigating an uncertain macroenvironment created by the reciprocal tariffs on goods entering the U.S., their primary market. By contrast, U.S. companies are bullish and believe they are well-positioned to navigate macroeconomic pressures. Still, across both regions, there is confidence in the sector and companies remain focused on advancing their technologies to address clinical needs – innovating, conducting trials, presenting data, raising funds, and delivering products that improve patients’ lives.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729205</guid>
      <pubDate>Mon, 02 Mar 2026 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729205-med-tech-outlook-2026-exits-financings-headwinds</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/2026-outlook-illustration.webp?t=1772488383" type="image/jpeg" medium="image" fileSize="763513">
        <media:title type="plain">2026 outlook virtual screen, business icons.jpg</media:title>
      </media:content>
    </item>
    <item>
      <title>M&amp;A activity drives infectious disease stock rebound</title>
      <description>
        <![CDATA[Infectious disease-focused biopharma companies continued their rebound into year-end, with the <em>BioWorld</em> Infectious Disease Index finishing 2025 up 68.55% after standing at a collective 28.98% at the end of October. The rally underscores a sharp reversal from earlier in the year, when the index had declined 17.83% by the end of April before recovering to a 4.34% gain by July.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729087</guid>
      <pubDate>Thu, 19 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729087-m-and-a-activity-drives-infectious-disease-stock-rebound</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Financial-analysis-illustration.webp?t=1752178170" type="image/jpeg" medium="image" fileSize="167882">
        <media:title type="plain">Hand, stylus pointing at graph on screen</media:title>
      </media:content>
    </item>
    <item>
      <title>ATF6 shapes liver cancer: from ER stress to inflammation</title>
      <description>
        <![CDATA[Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, representing approximately 75-85% of all cases. Often considered preventable, primary liver cancer ranks as the sixth most frequently diagnosed cancer and the third leading cause of cancer deaths worldwide. Through a multi-institutional effort, researchers have identified activated ATF6α as a driver of HCC that suppresses immune defenses, predicts response to immune checkpoint therapy, and represents a potential target for intervention.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728764</guid>
      <pubDate>Tue, 10 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728764-atf6-shapes-liver-cancer-from-er-stress-to-inflammation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-hepatocellular-carcinoma-HCC-liver.webp?t=1754576483" type="image/png" medium="image" fileSize="1872447">
        <media:title type="plain">Photomicrograph of hepatocellular carcinoma</media:title>
        <media:description type="plain">Photomicrograph of hepatocellular carcinoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>Cancer index surges 72% as Terns, Olema lead gains</title>
      <description>
        <![CDATA[The <em>BioWorld</em> Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow Jones Industrial Average (up 12.97%). The year featured standout gains, led by Terns Pharmaceuticals Inc., which surged 620%. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/728650</guid>
      <pubDate>Thu, 05 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728650-cancer-index-surges-72-as-terns-olema-lead-gains</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Business-growth-data-insight.webp?t=1645223399" type="image/png" medium="image" fileSize="906086">
        <media:title type="plain">Line graph arrow trending upward</media:title>
      </media:content>
    </item>
    <item>
      <title>BioWorld 2025 Year in Review</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/727250</guid>
      <pubDate>Mon, 22 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727250-bioworld-2025-year-in-review</link>
    </item>
    <item>
      <title>Trump administration impacts continue to roil the life sciences sector</title>
      <description>
        <![CDATA[<em>BioWorld</em> covers the Trump administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719453</guid>
      <pubDate>Thu, 05 Jun 2025 09:00:46 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719453-trump-administration-impacts-continue-to-roil-the-life-sciences-sector</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-white-house-president.webp?t=1588286767" type="image/png" medium="image" fileSize="1311489">
        <media:title type="plain">U.S. flag and White House podium</media:title>
      </media:content>
    </item>
    <item>
      <title>Healing the health divide: BioWorld reports on women’s health space</title>
      <description>
        <![CDATA[It’s difficult to fathom that the health of half the world’s population is underserved. But it’s a hard truth. Women’s health has traditionally focused on what Seema Kumar, the CEO of Cure, coined as the “bikini zone.” However, reproduction and breast health are a drop in the bucket when it comes to women’s health. In this multipart, in-depth series, <em>BioWorld</em> provides insight into the oft-overlooked space of women’s health, exposing the disparities in research and funding while looking toward future opportunities for bridging the gender gap in health care.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714815</guid>
      <pubDate>Thu, 21 Nov 2024 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714815</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Group-of-multigenerational-multiracial-women.webp?t=1731603262" type="image/jpeg" medium="image" fileSize="438228">
        <media:title type="plain">Group of multigenerational, multiracial women</media:title>
      </media:content>
    </item>
    <item>
      <title>Explore BioWorld’s comprehensive infographics collection</title>
      <description>
        <![CDATA[Discover a wealth of industry insights with <em>BioWorld</em>’s extensive collection of infographics, covering the latest trends and developments in both biopharma and med-tech. Our weekly infographics are curated to provide concise summaries of key topics: financings (IPOs, private financings, public/other and follow-on offerings), deals and M&As (top deals, and monthly value and volume), regulatory (including U.S. FDA and worldwide approvals), clinical trials and more. In addition, you’ll find access to <em>BioWorld</em>’s year-in-review reports, as well as special infographics about obesity, pain and addiction, biosimilars and the aging space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705938</guid>
      <pubDate>Tue, 20 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705938-explore-bioworlds-comprehensive-infographics-collection</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-with-bar-chart.webp?t=1707510184" type="image/jpeg" medium="image" fileSize="103185">
        <media:title type="plain">DNA with bar chart</media:title>
      </media:content>
    </item>
  </channel>
</rss>
